Last reviewed · How we verify
AERAS-402 3 x 10^9 vp
AERAS-402 3 x 10^9 vp is a Biologic drug developed by Aeras. It is currently in Phase 2 development. Also known as: AERAS-402.
At a glance
| Generic name | AERAS-402 3 x 10^9 vp |
|---|---|
| Also known as | AERAS-402 |
| Sponsor | Aeras |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AERAS-402 3 x 10^9 vp CI brief — competitive landscape report
- AERAS-402 3 x 10^9 vp updates RSS · CI watch RSS
- Aeras portfolio CI
Frequently asked questions about AERAS-402 3 x 10^9 vp
What is AERAS-402 3 x 10^9 vp?
AERAS-402 3 x 10^9 vp is a Biologic drug developed by Aeras.
Who makes AERAS-402 3 x 10^9 vp?
AERAS-402 3 x 10^9 vp is developed by Aeras (see full Aeras pipeline at /company/aeras).
Is AERAS-402 3 x 10^9 vp also known as anything else?
AERAS-402 3 x 10^9 vp is also known as AERAS-402.
What development phase is AERAS-402 3 x 10^9 vp in?
AERAS-402 3 x 10^9 vp is in Phase 2.
Related
- Manufacturer: Aeras — full pipeline
- Also known as: AERAS-402
- Compare: AERAS-402 3 x 10^9 vp vs similar drugs
- Pricing: AERAS-402 3 x 10^9 vp cost, discount & access